Acta Pharmaceutica Sinica B
SCI SCIE国际简称：ACTA PHARM SIN B 参考译名：医药学报 B
主要研究方向：Pharmacology, Toxicology and Pharmaceutics-General Pharmacology, Toxicology and Pharmaceutics 非预警期刊 审稿周期：19 Weeks
《医药学报 B》(Acta Pharmaceutica Sinica B)是一本由Elsevier BV出版的以Pharmacology, Toxicology and Pharmaceutics-General Pharmacology, Toxicology and Pharmaceutics为研究特色的国际期刊，发表该领域相关的原创研究文章、评论文章和综述文章，及时报道该领域相关理论、实践和应用学科的最新发现，旨在促进该学科领域科学信息的快速交流。该期刊是一本开放期刊，近三年没有被列入预警名单。该期刊享有很高的科学声誉，影响因子不断增加，发行量也同样高。
Acta Pharmaceutica Sinica B (APSB) is a bimonthly journal, in English, which publishes significant original research articles, rapid communications and high quality reviews of recent advances in all areas of pharmaceutical sciences — including pharmacology, pharmaceutics, medicinal chemistry, natural products, pharmacognosy, pharmaceutical analysis and pharmacokinetics.
Acta Pharmaceutica Sinica B期刊信息
- ISSN：2211-3835
- 出版语言：English
- 是否OA：开放
- E-ISSN：2211-3843
- 出版地区：CHINA MAINLAND
- 是否预警：否
- 出版商：Elsevier BV
- 出版周期：Monthly
- 创刊时间：2011
- 开源占比：0.9243
- Gold OA文章占比：99.37%
- OA被引用占比：NA
- 出版国人文章占比：0.66
- 出版撤稿占比：0
- 研究类文章占比：79.71%
Acta Pharmaceutica Sinica B CiteScore评价数据（2026年6月最新版）
| CiteScore | SJR | SNIP | CiteScore 指数 | ||||||||
| 24.4 | 3.439 | 2.516 |
|
名词解释：CiteScore 是衡量期刊所发表文献的平均受引用次数，是在 Scopus 中衡量期刊影响力的另一个指标。当年CiteScore 的计算依据是期刊最近4年（含计算年度）的被引次数除以该期刊近四年发表的文献数。例如，2022年的 CiteScore 计算方法为：2022年的 CiteScore =2019-2022年收到的对2019-2022年发表的文件的引用数量÷2019-2022年发布的文献数量 注：文献类型包括：文章、评论、会议论文、书籍章节和数据论文。
Acta Pharmaceutica Sinica B中科院评价数据
《新锐期刊分区表》（2026年3月发布）
| Top期刊 | 综述期刊 | 大类学科 | 小类学科 | ||
| 是 | 否 | 医学 | 1区 | PHARMACOLOGY & PHARMACY 药学 | 1区 |
Acta Pharmaceutica Sinica B JCR评价数据
2025-2026年最新版
| 按JCI指标学科分区 | 收录子集 | 分区 | 排名 | 百分位 |
| 学科：PHARMACOLOGY & PHARMACY | SCIE | Q1 | 8 / 356 |
97.9 |
| 学科：PHARMACOLOGY & PHARMACY | SCIE | Q1 | 3 / 356 |
99.3 |
Acta Pharmaceutica Sinica B历年数据统计
影响因子
中科院分区
Acta Pharmaceutica Sinica B中国学者发文选摘
-
1、Paeoniflorin alleviates hypobaric hypoxiatriggered lung injury through targeting MEK2 to modulate ERK2-SGK1 signalin
Author: Wu, Zhenhui; Wang, Yihao; Wang, Renjie; Gao, Rong; Li, Shubei; Tu, Bodan; Yin, Xiubing; Li, Maoxing; Zhou, Wei; Xu, Huanhua; Wu, Zhenfeng; Ma, Zengchun; Tang, Xianglin; Xiao, Chengrong; Gao, Yue
Journal: ACTA PHARMACEUTICA SINICA B. 2026; Vol. 16, Issue 3, pp. 1466-1488. DOI: 10.1016/j.apsb.2025.12.024
-
2、Targeting immunosuppressive network in glioblastoma: Emerging strategies to overcome immunodeficiency and enhance therapeutic efficac
Author: Zhou, Songlei; Zhang, Xiaokun; Lin, Jiayi; Ma, Fenfen; Chen, Hongzhuan; Chen, Jun; Luan, Xin
Journal: ACTA PHARMACEUTICA SINICA B. 2026; Vol. 16, Issue 3, pp. 1272-1291. DOI: 10.1016/j.apsb.2026.01.015
-
3、Mechanistic insights into ligand selectivity in m-and δ-opioid receptors beyond the message-address conceptual framewor
Author: Zhang, Xin; Song, Hongyan; Chen, Ruofan; Kong, Xinran; Wang, Jin; Li, Xinghua; Yu, Ye
Journal: ACTA PHARMACEUTICA SINICA B. 2026; Vol. 16, Issue 3, pp. 1530-1549. DOI: 10.1016/j.apsb.2025.11.039
-
4、AI-integrated microfluidics for drug screening: From single cell to organ-on-a-chi
Author: Yin, Hongyun; Li, Zheyu; Shen, Zinuo; Wang, Shiying; Du, Na; Cheng, Shibo; Zhou, Jie; Li, Yutao; Jia, Yanwei; Li, Ying
Journal: ACTA PHARMACEUTICA SINICA B. 2026; Vol. 16, Issue 3, pp. 1175-1200. DOI: 10.1016/j.apsb.2026.01.001
-
5、Inhibition of PGK1 enhances sensitivity to tyrosine kinase inhibitor in T315I-mutant leukemi
Author: Wang, Huijing; Jiang, Fengyu; Pan, An; Jin, Chenlong; Xue, Yangyang; Liu, Wenjie; Gu, Renjun; Zhou, Yanyu; Shen, Qiuhong; Ma, Tonghui; Yu, Xiaoxuan
Journal: ACTA PHARMACEUTICA SINICA B. 2026; Vol. 16, Issue 3, pp. 1449-1465. DOI: 10.1016/j.apsb.2025.12.039
-
6、Targeting RNA binding proteins with small-molecule inhibitors: Advances, challenges, and therapeutic opportunitie
Author: Shi, Yuning; Feng, Dazhi; Zhou, Jieya; Liu, Lihua; Li, Xinnan; Yuan, Zhenwei; Wu, Jianbing; Yao, Hong
Journal: ACTA PHARMACEUTICA SINICA B. 2026; Vol. 16, Issue 3, pp. 1292-1335. DOI: 10.1016/j.apsb.2025.12.010
-
7、TeroACT: A terpenoid bioactivity landscape and discovery platfor
Author: Shen, Xiaojuan; Yan, Shijia; Kang, Xu; Xu, Kangwei; Jian, Yongxing; Zeng, Tao; Wan, Guohui; Wu, Ruibo
Journal: ACTA PHARMACEUTICA SINICA B. 2026; Vol. 16, Issue 3, pp. 1233-1249. DOI: 10.1016/j.apsb.2025.12.036
-
8、A review of recent advances in generative artificial intelligence models for biomolecular science
Author: Jiang, Jian; Li, Daixin; Wang, Guilin; Hayes, Nicole; Shi, Yazhou; Qiu, Huahai; Zhang, Bengong; Zhou, Tianshou; Wei, Guo-Wei
Journal: ACTA PHARMACEUTICA SINICA B. 2026; Vol. 16, Issue 3, pp. 1201-1218. DOI: 10.1016/j.apsb.2025.12.012
Acta Pharmaceutica Sinica B同类期刊
-
公共卫生前沿
Frontiers In Public Health
中科院 3区 JCR Q1
-
药理学前沿
Frontiers In Pharmacology
中科院 2区 JCR Q1
-
生物医学与药物治疗
Biomedicine & Pharmacotherapy
中科院 2区 JCR Q1
-
探索肿瘤学
Discover Oncology
中科院 3区 JCR Q3
-
美康
Medcomm
中科院 1区 JCR Q1
-
Bmc精神病学
Bmc Psychiatry
中科院 2区 JCR Q1
-
Bmc神经病学
Bmc Neurology
中科院 3区 JCR Q3
-
公共卫生护理
Public Health Nursing
中科院 4区 JCR Q3
免责声明
若用户需要出版服务，请联系出版商：INST MATERIA MEDICA, CHINESE ACAD MEDICAL SCIENCES, C/O EDITORIAL BOARD OF ACTA PHARMACEUTICA SINICA, 1 XIANNONGTAN ST, BEIJING, PEOPLES R CHINA, 10005。